Dermira shares drop 63% after surprise acne clinical trial failure
March 05, 2018 at 10:58 AM EST
Acne is an enticing, if not particularly lifesaving, market for drugmakers, with more than $3 billion in revenue at stake.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|